Transcriptomic classification of prolactinomas and somatotropinomas identifies subtypes with variable resistance to treatment [0.03%]
转录组学分类的泌乳素瘤和生长激素瘤具有不同的治疗抵抗性亚型
Fabio Bioletto,Nesrine Benanteur,Maria Francesca Birtolo et al.
Fabio Bioletto et al.
Objective: Dopamine agonists and somatostatin analogs are commonly used in prolactinomas and somatotropinomas. Response to these therapies is heterogeneous. Whether resistance is linked to specific tumor subtypes or to sh...
Thyroid antibody status, thyroid function, and the risk of coronary heart disease and stroke: an individual participant data analysis from 14 cohorts [0.03%]
基于14项队列研究的个体参与者数据分析：甲状腺自身抗体状态、甲状腺功能与冠心病和卒中风险的关系
Ola Hysaj,Orestis Efthimiou,Tinh-Hai Collet et al.
Ola Hysaj et al.
Objective: The association of thyroid peroxidase antibodies (TPOAb) status with cardiovascular disease (CVD) risk, independent of thyroid function, remains unclear. We aimed to determine whether positive TPOAb is associat...
Letter to Editor: "Discordance and shortcomings of aldosterone suppression tests in primary aldosteronism" [0.03%]
论著letters to editor:"原发性醛固酮增多症患者醛固酮抑制试验的分歧和不足"
Luigi Marzano,Simonetta Friso
Luigi Marzano
Response to Letter to Editor: "Discordance and shortcomings of aldosterone suppression tests in primary aldosteronism" [0.03%]
对“原发性醛固酮增多症患者中抑制醛固酮试验的不一致和不足”的作者回信
Cheng-Hsuan Tsai,Stefanie Parisien-La Salle,Jenifer M Brown et al.
Cheng-Hsuan Tsai et al.
Biomarkers for Subtype Stratification in Primary Aldosteronism: Current and Future Perspectives [0.03%]
原发性醛固酮增多症亚型分层生物标志物的现状及未来展望
Tracy Ann Williams,Georgiana Constantinescu,Christina Pamporaki
Tracy Ann Williams
Primary aldosteronism, the most common endocrine cause of secondary hypertension, requires accurate differentiation of lateralised from bilateral subtypes to guide therapy: adrenalectomy for surgically curable lateralising forms versus life...
Accurate Diagnosis of Congenital Adrenal Hyperplasia due to CYP21A2 Variants Requires Promoter Analysis [0.03%]
CYP21A2 promotor分析可提高先天性肾上腺皮质增生症诊断的准确性
Marie Helene Schernthaner-Reiter,Stefan Riedl,Barbara Obermayer-Pietsch et al.
Marie Helene Schernthaner-Reiter et al.
Objective: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is an autosomal recessive disease mostly caused by compound heterozygous pathogenic CYP21A2 variants. CYP21A2 promoter analysis is ...
Efficacy Comparison of 6-Month Romosozumab Plus Denosumab Versus 12-Month Romosozumab in Koreans [0.03%]
浪漫索珠单抗联合地诺单抗与浪漫索珠单抗长效对韩国绝经后妇女的疗效比较：一项随机、双盲、平行对照研究
Seung-Eun Lee,Seong Hee Ahn,Beom-Jun Kim et al.
Seung-Eun Lee et al.
Objective: Romosozumab (Romo) rapidly increases bone mineral density (BMD), with approximately 70% of gains occurring within the first 6 months. The present study aimed to compare the efficacy of 6-month Romo followed by ...
The EndoCompass research roadmap: directions for the future of endocrine science [0.03%]
内分泌科学研究路线图：未来发展方向指南
Jérôme Bertherat,Anita Hokken-Koelega
Jérôme Bertherat
EndoCompass project: research roadmap for reproductive and developmental endocrinology [0.03%]
生殖和发育内分泌学的科研路线图：EndoCompass项目
Martine Cools,Csilla Krausz,Anders Juul et al.
Martine Cools et al.
Background: Endocrine science remains underrepresented in European Union research programs despite the fundamental role of hormone health in human wellbeing. Analysis of the CORDIS database reveals a persistent gap betwee...
EndoCompass project: the place of endocrinology in European research funding-an analysis of Horizon 2020 [0.03%]
欧盟地平线2020框架下欧洲内分泌学研究概览及资金流向——Endocompass项目分析报告
Srđan Pandurević,Yulia Matskevitch,Dirk De Rijdt
Srđan Pandurević
Background: Despite the substantial societal impact of prevalent endocrine diseases like obesity, diabetes, infertility, and thyroid disorders, plus over 440 rare endocrine conditions, it remains unclear whether endocrine...